EU DMF readiness
US DMF readiness
💉 Available also
in injectable form
Pentoxifylline is a xanthine derivative belongs to vasodilator agent. It is indicated for the treatment of peripheral vascular disease, including intermittent claudication on the basis of chronic occlusive arterial disease of the limbs and for the treatment of acute arterial circulatory disorders of the eye.
It is formulated as extended release tablets for oral route of administration and as solution for injection infusion for intravenous route of administration.
Mechanism of action:
Pentoxifylline inhibits phosphodiesterase, resulting in increased levels of cyclic adenosine monophosphate (cAMP) in erythrocytes, endothelium, and the surrounding tissues. This leads to vasodilation, improves erythrocyte flexibility, and enhances blood flow. In addition, the increased level of cAMP in platelets inhibits platelet aggregation, which may contribute to a reduction in blood viscosity.
Products protected by valid patents are not offered for commercial sale in countries where the sale of such products constitutes patent infringement but are offered solely for uses reasonably related to the development and submission of information under a law regulating the manufacture, use or sale of drugs. It is within the buyer’s responsibility and liability to check the patent situation of the product in the imported market(s).
for the R&D and Production of highly active substances
with an OEL value of 10 ng/m3 (OEB 6).
The HP API investment includes separate process
laboratories (PDL), analytical laboratories (ADL)
with the possibility of performing Quality Control
analyses, and a GMP kilo-lab production line with
volume up to 1.5 kg with potential volume increase.